Vector Capital portfolio company Certara, a provider of drug discovery, development software and scientific consulting services, has entered into a definitive agreement to acquire Simcyp, a provider of a modeling and simulation platform for predicting the fate of drugs in virtual populations. Certara was formed in 2008 through the merger of Vector-backed companies Pharsight and Tripos.
